Company intelligence / Profile preview

Thyroscope

South Korea

Ownership: Private
Development stage: Other

Overview

Digital device GLANDY is the world's first digital monitoring solution for thyroid disease and eye disease, with K-FDA clinical approval and ongoing regulatory procedures for global approvals. Early clinical adoption and research partnerships in Korea; pre-submission to US FDA completed in 2021[1][3].

Therapeutic areas: Endocrinology
Modalities: DeviceAI-based digital biomarker
Industry: Physiological Monitoring

Partnerships

HospitalsPharmaceutical companiesMedical device companiesWearable device manufacturers

Beyond the preview

Go deeper on Thyroscope.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thyroscope.

Explore the full profile